key: cord-1049971-h6q3rkr7
authors: Li, Ruiyun; Bjørnstad, Ottar N.; Stenseth, Nils Chr.
title: Prioritizing vaccination by age and social activity to advance societal health benefits in Norway: a modelling study
date: 2021-08-15
journal: Lancet Reg Health Eur
DOI: 10.1016/j.lanepe.2021.100200
sha: eb9afa28c4345b5cca6f2566e6700266e6a74343
doc_id: 1049971
cord_uid: h6q3rkr7

BACKGROUND: Vaccination has the proven effectiveness in reducing disease burden. As the emergency program is moving towards completion in many countries, there is a new urgency to appropriately assess the societal health benefits in both the near and longer term. METHODS: Using an age-structured mathematical infection model, we evaluate the gains achievable by adopting the ongoing and the possible alternative vaccination strategies to reduce COVID-19 infections in the current pandemic as well as during the future successive waves in Norway. We explicitly consider three allocation strategies, with single focus group on either (i) the older age groups at high risk of dying or (ii) the core-sociable groups at high risk of exposure and onwards transmission, versus strategies focusing on both groups by (iii) switching among the high-risk to the core-sociable. FINDINGS: Following the Norwegian Institute of Public Health (FHI) schedule, we estimate that allocating vaccines in an age-descending order may reduce around one-third of the infections; while strategy considering age-specific sociability may contribute to an additional ∼10% fewer infections. INTERPRETATION: A key insight of our study is that prioritizing the high-risk and core-sociable groups may maximize the benefit due to both direct and indirect protections, and thus achieving the larger societal health benefits. Our analyses provides a quantitative tool to planning of future campaigns for Scandinavian and other countries with comparable infection-fatality ratios, demographies and public health infrastructure. FUNDING: Research Council of Norway and the Penn State University.

As mass vaccination campaigns commence worldwide, the most pressing question is how to achieve the greatest societal health benefits into the future. Most current policies towards attaining the goal of reducing COVID-19 related mortality by vaccinating the high-risk groups [1] . While evidence have shown a proven effectiveness of these policies in the early stage of vaccine rollout [2À7], historical evidence from other infectious diseases suggests that direct protective measures may lose primacy in the intermediate and long term [8] . This motivates us to leverage the mathematical tools to tailor vaccine prioritization in the realworld setting.

The Norwegian Institute of Public Health (FHI) has scheduled the country's Covid-19 vaccination program, with the aim of vaccinating all adults over the age of 18 by mid-July 2021 [9] . The program, as broadly adopted across the world, prioritizes at-risk groups, allocating doses in descending order of age. Of note, the relatively low mortality rate and thus the infection-fatality ratio in Norway [10] may implicate alternative vaccination strategies. Here we, using an agestructured mathematical infection model, assess the effectiveness of the current strategy and its effectiveness relative to possible alternative strategies. We assess the effectiveness by focusing on the reduction in the number of infected people in the population, as this is a key metric when considering the number of hospitalizations and thus the health burden locally and for the country as a whole. Vaccine-induced reduction in virus circulation reduces health cost and the ultimate burden of mortality.

CoV-2 dynamics with diverse vaccination roll-out strategies. The realistic nature of our age-structured model is represented by observed mixing pattern among age groups and the empirically documented age structure in the population. We include a mobilityterm to link the reduction of contacts to reduced mobility. Details of the model and simulations are presented in the supplement. The model captures how transmission happens from symptomatic (I s ) and asymptomatic (I a ) infections with a force of infection (λ) that depends on age (i): 

dR i dt

The force of infection on susceptibles in age-class i at time t is

where bðtÞ is the rate of seasonal transmission and C ij is the normalized contact rate between age group i and j. We consider an all-or-nothing vaccine which provides perfect protection to a fraction, defined by vaccine efficacy, of the vaccinated individuals. To appropriately model the fraction of individuals vaccinated during a campaign, we define the rate of vaccination (Q i ) as Àlogð1 À P i Þ=D i where P i and D i is the vaccine coverage and duration of vaccination in age group i, respectively; q is the vaccine efficacy (taken as 50%À90% in this analysis) [12] . We assume a one-year immunity duration (1=v) [13, 14] , and the same rate of the loss of immunity (v) for the recovered or vaccinated individuals. We assume an average latent period (1=s) and infection period (1=g) as 3 and 5 days, respectively [15] . The age-dependent fraction of symptomatic infections is characterized by r 2 [15] . Details of model parameters are provided in Table S1 . We initialize the analysis by assessing the effectiveness of the ongoing vaccination program in 23 Norwegian cities covering the range of demography. We assume that all cities follow the recommended prioritization from the FHI conservative vaccination schedule and vaccinate at the same rate. Thus, we translate the number of doses to the group-specific coverage in each city. To quantitatively assess the effectiveness of the current schedule, we consider an alternative strategy based on the sociability of various groups that would allocate vaccines in a descending rank of average age-specific number of daily contacts [16] . Across cities and strategies, we estimate the reduction of infections and mortality by the end of and two months after the campaign (i.e. mid-July and mid-September).

The model allows us to assess the effectiveness of different strategies across various annual vaccination campaigns. We consider programs that generally prioritize the vaccination for the elderly (75+ yr) but subsequently implement three strategies for the rest of the population: strategies with single focus groups on either (i) the older age groups at high risk of dying (hereafter "the age-focused strategy") or (ii) the core-sociable groups at high risk of exposure and onwards transmission (hereafter "the sociability-focused strategy"), versus strategies focusing on both groups by (iii) switching among the highrisk to the core-sociable (hereafter "the switched strategy"). For each strategy, we evaluate the reduction of infections and mortality over a year for 23 cities and Norway as whole.

The funders have no role in study design, data collection, data analysis, interpretation and writing of the report.

We first examine the effectiveness of the ongoing FHI vaccine rollout strategy in settings spanning the demographic diversity of Norwegian cities by the end of the current campaign (Fig. 1A , Supplementary Table S2 ). Across cities and efficacies, the FHI strategy, allocating vaccines in the age-descending order, is predicted to lead to a median of 27% (21%À41%) fewer infections as compared to the absence of vaccination. Of the cities, Kristiansand, A lesund and Arendal would expect the greatest reduction of infections, achieving gains of over 35%. Assuming the same number of doses as scheduled by the FHI, we demonstrate that allocating the doses by the sociability-descending strategy would be more effective than the scheduled age-descending strategy because of lowered circulation and thus enhanced indirect protection. Across cities we project a median of 35% (25%À47%) less infections by using the alternative strategy, though the incremental gain is predicted to vary among the cities. The variation of the effectiveness among cities may in part be due to the difference in the strength of travel-restrictions and thus the

Evidence before this study

We did a literature search in PubMed for studies assessing vaccine allocation strategies of SARS-CoV-2 in English until May 2021, using the following key search terms: "vaccine", "allocation", "roll-out", "Europe", "Norway" and "strategy". Preliminary evidence supports that vaccination targeting at the highrisk old people is the key to reducing the burden of mortality. However, projecting vaccine allocation strategies in the near and medium term, in particular in countries with low mortality rate, has not been fully investigated.

Our study evaluates the gains achievable by adopting the ongoing and the possible alternative vaccination strategies to reduce COVID-19 infections in the current pandemic as well as during the future successive waves in Norway. A key insight of our study is that prioritizing the high-risk and core-sociable groups may maximize the benefit due to both direct and indirect protections, and thus achieving the larger societal health benefits. Such timely finding points to the urgency to keep high-risk and high-contact groups visiting vaccine-providing centers during the campaign to best manage the future circulation.

Evidence of this study offers new guidelines and a quantitative tool for considering prioritization of vaccination for Scandinavian and other countries with comparable demographies, public health infrastructure and infection-fatality ratios. extent to which social contacts are modulated. Over two months after the end of the campaign, we estimate a median of 23% (19%À31%) and 29% (21%À40%) less infections by the FHI and the alternative strategy, respectively (Fig. 1B) . Further analysis shows that the sociability-descending strategy may of the equivalent effectiveness with the scheduled age-descending strategy in terms of averting the mortality in the population (Fig. S1 ).

Given the likely transition towards endemicity [11, 14] , projecting trajectories to intermediate term circulation under different vaccination strategies is key to optimizing management. To highlight this conceptual issue, we lay out a framework considering annual vaccination campaign with prioritization to the elderly (over 75+ yr) and differing strategies to the rest of the population (Fig. 2) .

Assuming a one-year immunity duration, a fully re-opened society and an approx. 25% vaccine cover deficit (i.e. the proportion of the under 20 yrs), we first project the reduction of infections over a year for each city under scenarios with differing vaccine efficacies (Fig. 3A, Supplementary Table S3 ). By distributing the vaccination to core-sociable groups, either through the sociability-focused or switched strategy, our model predictions suggest a slightly larger reduction (»2%) in the overall infections. This, using Oslo as example, is equivalent to up to 933 less infections than the age-focused strategy, assuming an 80% efficacy. Of note, the effectiveness of vaccination is associated with the vaccine cover deficit. Assuming a low (10%) deficit (Fig. 3B, Supplementary Table S3 ), we demonstrate a higher effectiveness of the switched strategy across cities, leading to a median of 25% (22%À30%) reduction of infections. If vaccinating with single focused groups, however, we project that the gains would be lowered by around 2%. For example, vaccination focus on single groups would lead to up to 652 fewer infections than the switched strategy in Oslo, assuming an efficacy of 80%. Across cities we document a comparable reduction of mortality by using the switched and age-focused strategies (Fig. S2) .

Zooming out the city-level evaluation to Norway as a whole is fundamental to guide policy options. Our scenario analysis shows that the relative effectiveness among strategies is highly dependent on the rate of vaccination and the extent that vaccination can modulate the dynamics of SARS-CoV-2 which in turn related to vaccine cover deficit (Fig. 4A,B) . Assuming »25% deficit, vaccinating the high-risk older age groups is predicted to have the smallest effect on slowing and reducing the infected fraction. By contrast, the sociability-focused or the switched strategy may have stronger modulation on epidemic dynamics. If lowering the deficit to 10%, vaccination focusing on both the high-risk and core-sociable groups may have the greatest effect on the transmission, leading to the greatest reduction in the burden of infection over a year-long campaign (Fig. 4C ).

Using an age-structured mathematical model, we have assessed the societal health benefits of the ongoing vaccination program and projected public health benefits to various roll-out strategies of future campaigns. Following the FHI vaccination schedule, we estimate that allocating vaccines in an age-descending order may reduce around one-third of the infections. An alternative strategy of allocating vaccines according to age-specific sociability may contribute to an additional »10% fewer infections, together with a comparable reduction of mortality. As such vaccination targeting the high contact groups may be more advantageous, in countries such as Norway with relatively low mortality rate [10] . In settings with similar infectionfatality ratios [17, 18] , our framework provides a quantitative tool for considering prioritization of vaccination for Scandinavian and other countries with comparable demographies and public health infrastructure.

Our projections for future vaccination campaigns highlight that prioritizing the high-risk and core-sociable groups may maximize the benefit due to both direct and indirect protections, and thus achieving the larger societal health benefits. This finding points to the urgency to keep high-risk and high-contact groups visiting vaccineproviding centres during the campaign to best manage the future circulation. To prevent transmission among these key groups, we proposed that prioritizing the older age groups who are at high risk of dying and switching to high transmitters in consecutive stages of the campaign would be an appropriate approach. More importantly, we Vaccine roll-out strategy in annual campaign. The elderly (over 75 yr), the high-risk older age groups and the core-sociable groups are identified from the (A) demography and the (B) marginal contacts over age groups. Across strategies (C-E) the elderly were fully vaccinate in the first period. Over the next 2 periods, strategies differ in the focused groups of the rest population. (C) 'the age-focused strategy' prioritizes and fully vaccinates the high-risk older age groups, and then, depending on the vaccine supply, fully/partially vaccinate the younger age classes. (D) 'the sociability-focused strategy' prioritizes and fully vaccinates the core-sociable groups in the second period, moving to all the unvaccinated individuals using the rest of the doses. (E) 'the switched strategy' switches the prioritization from the high-risk to the core-sociable ones in the two consecutive periods, together with the unvaccinated individuals in the last period. The coverage is dependent on the total vaccine supply. demonstrate that low vaccine deficit due to high willingness of the public for the vaccination and high vaccine supply is essential. Regardless of the demography, countries with low vaccine deficit should consider a two-pronged plan of targeting the high-risk and core-sociable groups.

Projecting our framework to other countries will need to tailor the social mixing and infection profile in each context. First, we assume a consistent social mixing patterns across cities. Specifying the mixing, together with the demography, will better characterize the heterogeneities in disease dynamics and contextualize the effectiveness of vaccination. Second, infectiousness and proportion of asymptomatic infections may vary over time, and thus are crucial directions to extend our study. Lastly, only the elderly over age 75 is considered in the prioritized groups when applying the framework to highlight the conceptual issue of relative effectiveness among strategies for future vaccination campaigns. Relaxing such assumption is the key to refining and translating our findings from broader range of perspectives such as economics.

RL and NCS conceived and designed the analysis. RL performed the analysis. RL, ONB and NCS interpreted the results. RL wrote the manuscript. RL, ONB and NCS critically revised the manuscript and approved the final version.

Not applicable.

Code for the analysis is deposited in https://github.com/ ruiyunli90/Corona-vaccine-Norway

The authors have nothing to disclose.

Framework for equitable allocation of COVID-19 vaccine

Modeling strategies for the initial allocation of COVID-19 vaccines

Modeling allocation strategies for the initial SARS-CoV-2 vaccine supply

Model-informed COVID-19 vaccine prioritization strategies by age and serostatus

Modelling optimal vaccination strategy for SARS-CoV-2 in the UK. 2020

Vaccine optimization for COVID-19: Who to vaccinate first?

Dynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers

Natural immune boosting in pertussis dynamics and the potential for long-term vaccine failure

A-B) trajectories of the infected fraction with 80% vaccine efficacy and (C) effectiveness in reducing infections over a year across efficacies by using the age-focused (yellow), the sociability-focused (green) and the switched (black) strategies is projected for Norway as whole

The National Institute of Public Health. Vaccination Calendar

Our World in Data. Case fatality rate of the ongoing COVID-19 pandemic

A general model for the demographic signatures of the transition from pandemic emergence to endemicity

Epidemics: Models and Data using R

The time course of the immune response to experimental coronavirus infection of man

Immunological characteristics govern the transition of COVID-19 to Endemicity

Age-dependent effects in the transmission and control of COVID-19 epidemics

Social contacts and mixing patterns relevant to the spread of infectious diseases

Evaluating and optimizing COVID-19 vaccination policies: a case study of Sweden

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection fatality rate among elderly danes: A cross-sectional study on retired blood donors

This work is funded by the Research Council of Norway Researcher Project for Young Talents 325041 (RL) and COVID-19Seasonality Project 312740 (NCS), and the Penn State University Seed-Funded COVID-19 Project (ONB).

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.lanepe.2021.100200.